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INTRODUCTION
Bovine respiratory disease (BRD) complex is a 
well-documented, multi-faceted disease syndrome in-
volving environmental factors, host factors, and man-
agement practices affecting the health and performance 
of feedlot calves (Kelly and Janzen, 1986; Smith, 1998). 
Marketing and shipment of cattle are associated with 
stress prior to feedlot arrival, which increases the risk 
for BRD of fed cattle (Lofgreen et al., 1978; Camp et al., 
1981). Mass medication, also known as metaphylaxis, 
has been used to prevent BRD in groups of cattle arriv-
ing at feedlots with over half of United States feedlots 
using metaphylaxis on at least some groups of cattle 
near the time of feedlot arrival (USDA, 2011).
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ABSTRACT: The objective of this project was to 
evaluate the effects of antimicrobials approved for par-
enteral metaphylactic use in feeder and stocker calves 
on morbidity and mortality for bovine respiratory dis-
ease with the use of a mixed treatment comparison 
meta-analysis. An initial literature review was conduct-
ed in April 2016 through Pubmed, Agricola, and CAB 
(Commonwealth Agricultural Bureau) for randomized 
controlled trials for metaphylaxis antimicrobial admin-
istered parentally to incoming feedlot or stocker calves 
within 48 h of arrival. The final list of publications 
included 29 studies, with a total of 37 trials. There were 
8 different metaphylactic antimicrobials. Final event 
outcomes were categorized into bovine respiratory dis-
ease (BRD)  morbidity cumulative incidence d 1 to ≤ 
60 of the feeding period, BRD morbidity cumulative 
incidence d 1 to closeout of the feeding period, BRD 
mortality cumulative incidence d 1 to closeout of the 
feeding period, and BRD retreatment cumulative inci-
dence morbidity d 1 to closeout of the feeding period. 
Network meta-analysis combined direct and indirect 
evidence for all the event outcomes to determine mean 
odds ratio (OR) with 95% credibility intervals (CrIs) 
for all metaphylactic antimicrobial comparisons. The 
“upper tier” treatment arms for morbidity d 1 to ≤ 60 
included tulathromycin, gamithromycin, and tilmico-
sin. For BRD mortality cumulative incidence d 1 to 
closeout and BRD retreatment morbidity d 1 to close-
out, classifying the treatment arms into tiers was not 
possible due to overlapping 95% CrIs. The results of 
this project accurately identified differences between 
metaphylactic antimicrobials, and metaphylactic anti-
microbial options appear to offer different outcomes 
on BRD morbidity and mortality odds in feedlot cattle.
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Multiple antimicrobials are currently available and 
used metaphylactically to decrease negative effects of 
BRD in groups of feedlot cattle, and the decision to im-
plement a specific antimicrobial is dependent on the ef-
ficacy and cost effectiveness (Nickell and White, 2010). 
Clinical trials have been conducted to investigate the ef-
ficacy of antimicrobials for the treatment and control of 
BRD, and metaphylaxis uses have been investigated as 
a method to reduce morbidity and mortality associated 
with BRD in feedlot cattle (DeDonder and Apley, 2015; 
Ives and Richeson, 2015). Meta-analysis and system-
atic reviews of the available literature have been previ-
ously performed to summarize published clinical trials 
for antimicrobial treatment of clinical BRD cases and 
for specific antimicrobials used metaphylactically, but 
no systematic review or meta-analysis has been pub-
lished that summarizes clinical trials for all approved 
parenterally administered metaphylactic antimicrobi-
als (Van Donkersgoed, 1992; Wellman and O’Connor, 
2007; Wileman et al., 2009; Nickell and White, 2010).
A mixed treatment comparison (MTC) meta-
analysis can assess indirect comparisons between an-
timicrobials where an actual clinical trial was not per-
formed (Higgins and Whitehead, 1996; Lu and Ades, 
2004; Jansen et al., 2011). The indirect comparison 
have been proven to be realistic estimates of disease 
risk when direct estimates are not available (O’Connor 
et al., 2016). The MTC of meta-analysis has been 
done frequently in the human medical field (Mills et 
al., 2009; Roever and Biondi-Zoccai, 2016; Shao et 
al., 2016), and has previously evaluated antimicro-
bial efficacy for treatment of BRD (O’Connor et al., 
2013). The objective of this research was to evaluate 
the effect of parenterally administered metaphylactic 
antimicrobials approved for feeder and stocker calves 
on morbidity and mortality due to BRD using a MTC 
meta-analysis. These results should aid in the under-
standing of the effect of metaphylactic antimicrobial 
options on clinically important BRD outcomes.
MATERIALS AND METHODS
Literature Search
An initial literature review was conducted in April 
2016 by a reviewer (KA) using, AGRICOLA (all years 
available), Commonwealth Agricultural Bureau (all 
years available), and Pubmed (all years available) for 
retrieval of topics relevant to the objective. The search 
terms included [beef OR cattle OR cow or OR bovine 
OR steer OR heifer OR calf OR calves] AND [metaphyl* 
OR prophylactic]. An initial search revealed a total of 
3753 papers. Titles of peer reviewed papers published 
in English that included the search terms were examined 
for relevance. The initial search process was repeated 
with another independent reviewer (RL). Abstracts of 
relevant manuscripts were reviewed, and if agreed rel-
evant, the full manuscript was acquired. Relevant manu-
scripts obtained by both reviewers were compared and 
only those relevant to the objective were fully reviewed. 
A third party reviewer was utilized if a disagreement be-
tween the first 2 reviewers occurred over the relevance 
of a manuscript. Studies were excluded if randomization 
was not reported. In addition, metaphylaxis antimicrobial 
had to be administered parentally to incoming feedlot 
or stocker calves within 48 h of arrival. Studies using 
young, lightweight veal or dairy calves were excluded; 
however, if age, weight, or type of cattle were specifi-
cally described and were consistent with cattle arriving 
at U.S. feedlots, the study was included in the analysis. 
Metaphylactic administration had to be the only treat-
ment variable. Only naturally occurring BRD was used 
as study outcome and challenge studies were excluded 
from the analysis. Blinding was reported in 24 trials, and 
was not reported in 16 trials, all trials were included in 
the statistical analysis regardless of blinding criteria. In 
2 trials, blinding was reported to have not been possible 
due to the person implementing the BRD treatment pro-
tocol having prior knowledge of previous antimicrobi-
als administered metaphylactically (Van Donkersgoed, 
2012; Van Donkersgoed and Merrill, 2013a).
Data Extraction
Outcome data comparing a metaphylactic antimi-
crobial to another antimicrobial or a control within each 
trial within each study was extracted (Larson and Step, 
2012; Theurer et al., 2015). If a study contained multiple 
trials, the data from each trial were extracted separately. 
All data for each trial were extracted by a single reviewer 
(KA), and verified by a second reviewer (RL). A treat-
ment arm was considered a different antimicrobial for 
each trial. For example, if a trial consisted of antimicro-
bial A and B, this trial included two different treatment 
arms. For each trial, the following data were extracted: 
the interventions (antimicrobial) for each treatment arm, 
the number of animals enrolled in each treatment arm, 
and event occurrence for each treatment arm (Table 1). 
Event occurrence included morbidity, retreatment mor-
bidity, and mortality related to BRD. Data were aggregat-
ed between treatment arms within a trial if the difference 
between those treatment arms was due to a difference in 
the post metaphylactic interval or route of antimicrobial 
administration. For example, if the difference between 
2 antimicrobial groups was the dosage of the antibiotic 
(tilmicosin 10 mg/kg and 20 mg/kg), then antimicrobials 
were aggregated to a single antimicrobial group (tilmico-
sin; Corbin et al., 2009). Also, if the difference between 2 
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Table 1. Data extracted from 37 individual trials and 29 studies included in the mixed treatment comparison 
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ceftiofur/gamithromycin 1853 931/922 205 354/295 – – – (Amrine et al., 2014)
control/gamithromycin 87 44/43 582 12/8 – – – (Baggott et al., 2011)
control/gamithromycin 242 121/121 390 32/8 – – – (Baggott et al., 2011)
control/gamithromycin 227 114/113 430 32/6 – – – (Baggott et al., 2011)
tilmicosin/oxytetracycline/ 
   tulathromycin
9910 3304/3302/ 
3304
300 – 464/562/113 62/84/10 179/218/26 (Booker et al., 2007)
tilmicosin/ceftiofur 11,605 3870/7735 256 – 1116/2120 423/626 713/1222 (Booker et al., 2007)
control/tilmicosin 1000 200/800 207 – 68/164 27/54 23/58 (Corbin et al., 2009)
control/tilmicosin 997 200/797 265 – 137/374 1/14 53/107 (Corbin et al., 2009)
control/tilmicosin 64 32/32 224 23/15 – – – (Duff et al., 2000)
control/oxytetracycline 1793 893/900 120 71/30 – – – (Fazzio et al., 2015)
control/florfenicol 60 30/30 230 13/10 – – – (Frank et al., 2002)
control/florfenicol 42 21/21 230 12/9 – – – (Frank et al., 2002)
control/tilmicosin 57 28/29 170 13/0 – – – (Galyean et al., 1995)
control/tilmicosin 116 58/58 191 19/7 – – – (Galyean et al., 1995)
control/tilmicosin 121 62/59 232 27/7 – – – (Galyean et al., 1995)
control/tilmicosin 400 200/200 273 113/51 123/60 0/2 12/8 (Guthrie et al., 2004)
control/TMS/oxytetracycline 900 300/300/300 325 139/133/97 172/169/140 10/9/6 – (Harland et al., 1991)
control/gamithromycin 308 154/154 293 64/34 – – – (Lechtenberg et al., 2011)
control/gamithromycin 159 53/106 256 34/15 – – – (Lechtenberg et al., 2011)
control/florfenicol 108 54/54 271 16/18 – – – (Martin et al., 2007)
control/tilmicosin 199 100/99 215 54/15 – – – (McClary and Vogel, 1999)
control/tilmicosin/ 
   oxytetracycline
1806 601/602/603 300 254/117/157 – – – (Morck et al., 1993)
tilmicosin/tulathromycin 293 147/146 219 100/48 – 20/5 – (Nickell et al., 2008)
control/gamithromycin 250 125/125 350 43/6 – – – (Rossi et al., 2010)
oxytetracycline/ 
   gamithromycin
470 235/235 345 34/4 – – – (Rossi et al., 2010)
tulathromycin/ 
   gamithromycin
1136 568/568 325 83/53 – – – (Rossi et al., 2010)
control/tilmicosin 305 154/151 337 35/8 – – – (Schumann et al., 1990)
control/tilmicosin 205 103/102 269 21/2 – – – (Schumann et al., 1991)
tilmicosin/oxytetracycline 10,989 5494/5495 281 – 1064/1239 77/85 409/454 (Schunicht et al., 2002)
tilmicosin/ceftiofur 385 194/191 – 14/18 – – – (Step et al., 2007)
control/tilmicosin/ 
   tulathromycin
2336 783/784/769 312 – 112/45/16 24/11/8 – (Tennant et al., 2014)
tulathromycin/ 
   gamithromycin
2529 1266/1263 230 274/361 – – – (Torres et al., 2013)
tilmicosin/gamithromycin 5000 2500/2500 312 – 480/320 10/15 81/44 (Van Donkersgoed, 2012)
tilmicosin/tildipirosin 4500 2250/2250 336 – 608/338 20/20 79/54 (Van Donkersgoed and  
Merrill, 2013a)
control/tilmicosin 4314 2157/2157 348 – 259/173 9/2 53/33 (Van Donkersgoed and  
Merrill, 2013b)
tilmicosin/tulathromycin 4494 2250/2244 274 – 315/67 5/1 28/7 (Van Donkersgoed  
et al., 2008)
control/tilmicosin 1096 550/546 259 298/165 317/185 23/9 50/22 (Vogel et al., 1998)
1Experimental units per antimicrobial group.
2Allocation weight in kilograms.
3BRD morbidity cumulative incidence d 1 to ≤ 60 of the feeding period.
4BRD morbidity cumulative incidence d 1 to closeout of the feeding period.
5BRD mortality cumulative incidence d 1 to closeout.
6BRD retreatment cumulative incidence d 1 to closeout.
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treatments with the same antimicrobial was due to post-
metaphylactic interval (ceftiofur 3 PMI and 7 PMI), then 
antimicrobials were aggregated to a single antimicrobial 
group (ceftiofur; Booker et al., 2006).
BRD morbidity included calves that were enrolled 
in the trial and had to be treated for BRD. The proto-
col for BRD diagnosis needed to be described in the 
report, and had to include rectal temperature, clinical 
signs consistent with BRD, and administration of an 
antimicrobial. If this protocol was not outlined, the 
corresponding author was contacted for clarification of 
the protocol to diagnose BRD. Two corresponding au-
thors were contacted and responded for clarification. If 
the results were given as a percent of animals in each 
treatment arm, then the event occurrence was extracted 
based on the total number of animals enrolled in that 
trial for each of the treatment arms. If the numerator 
and denominator used to calculate the percent could not 
be distinguished, the data were excluded in the analysis.
BRD retreatment morbidity was classified as ani-
mals initially diagnosed with BRD and treated with 
an antimicrobial that required an additional antimicro-
bial for BRD. If mortality data were not provided in 
the trial, or BRD mortality could not be distinguished 
from the overall mortality events, the mortality data 
were excluded in the analysis.
Treatment periods were established as either d 1 to ≤ 
60 of the feeding period or d 1 to the end of the feeding 
period, and a single event could be classified as occur-
ring in both treatment periods. The end of the feeding 
period is referred to as closeout. Day 1 included the day 
the metaphylactic treatment was given. If the monitoring 
period of the study was less than 60 d, the data were only 
included in the d 1 to ≤ 60 of the feeding period category. 
Trial days ranged from 7 to 60 d and this variability was 
accounted for in the analysis. If a trial included event re-
sults from d 1 to ≤ 60 over multiple periods, the event 
results closest to 60 d was included. Any trial data that 
did not fall into one of these categories were excluded.
Multiple Treatment Comparison Analysis
The effectiveness of each individual treatment arm 
for the BRD morbidity d 1 to ≤ 60 was examined us-
ing the binomial likelihood, complimentary log-log link, 
random-effects model for combining direct and indi-
rect evidence in mixed treatment comparisons using a 
Bayesian approach as previously described (Higgins and 
Whitehead, 1996; Lu and Ades, 2004; Dias et al., 2010). 
This model assumes that the outcome for BRD morbidity 
d 1 to ≤ 60 is time dependent, and based on the differing 
lengths of each treatment arm the time until an event oc-
curs has an exponential distribution (Dias et al., 2011). 
Differing days at risk were accounted for BRD morbidity 
d 1 to ≤ 60, for example if a trial period was 14 d, the 
days at risk would be 14/60 = 0.23 d at risk. Trial days 
were only accounted for in trials included in the BRD 
morbidity d 1 to ≤ 60 outcome. The effectiveness of each 
individual treatment arm for BRD morbidity, BRD mor-
tality, and BRD retreatment d 1 to ≤ closeout was exam-
ined using the binomial likelihood, logit link, random-
effects model for combining direct and indirect evidence 
in mixed treatment comparisons using a Bayesian ap-
proach similar to d 1 to ≤ 60 d evaluation. (Higgins and 
Whitehead, 1996; Lu and Ades, 2004; Dias et al., 2010). 
This model assumes that the proportional odds assump-
tion holds, that all trials occur within the same time pe-
riod, and further days at risk would not affect the differ-
ences between events (Dias et al., 2011). The code was 
called through WinBUGS with R to fit the model with 
the R2Winbugs package (Dias et al., 2011).
A homogeneous variance was assumed and uni-
formed priors were used for the standard deviation, σ for 
each of the BRD morbidity d 1 to ≤ 60 d, BRD morbidity 
d 1 to closeout, BRD mortality d 1 to closeout, and BRD 
retreatment morbidity d 1 to closeout models. Two uni-
form standard deviation priors were compared for each 
individual outcome model, σ ~ uniform (0, 5) vs. σ ~ uni-
form (0, 2), and based on narrower credibility intervals 
(CrIs) and lower deviance information criterion (DIC), 
σ ~ uniform (0, 5) was used in the final code. Gelman-
Rubin diagnostics were performed to determine best con-
vergence for chains (Gelman and Rubin, 1992). A total of 
2 chains were used for each model, each with 120,000 
iterations, with the first 20,000 iterations discarded. The 
output from the code was the posterior mean for odds 
ratio between the treatment arm comparisons with cor-
responding 95% CrIs. Treatment arms with the least OR 
and with corresponding overlapping 95% CrIs were clas-
sified as “upper tier.” Treatment arms with the greatest 
OR and with corresponding overlapping 95% CrIs were 
classified as “lesser tier.” Treatment arms in between the 
greatest and least OR and with corresponding overlap-
ping 95% CrIs were classified as “middle tier.”
RESULTS
After initial screening for relevant titles and abstracts, 
a final list of 170 publications was retrieved and evalu-
ated. From these publications, 29 studies, with a total of 
37 trials met all inclusion criteria. The length of the trial 
periods ranged from 7 to 293 d. Only BRD morbidity 
cumulative incidence is reported for treatment period d 
1 to ≤ 60 of the feeding period and all event outcomes 
(BRD morbidity, mortality, and retreatment morbidity) 
are reported for treatment period d 1 to closeout.
Figure 1 shows a network of the different treatment 
arms included for each individual event outcome. BRD 
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morbidity cumulative incidence d 1 to ≤ 60 included 62 
treatment arms from 27 trials, BRD morbidity cumu-
lative incidence d 1 to closeout included 37 treatment 
arms from 13 trials, BRD mortality cumulative inci-
dence d 1 to closeout included 40 treatment arms from 
14 trials, and BRD retreatment morbidity cumulative in-
cidence d 1 to closeout included 26 treatment arms from 
11 trials (Fig. 1). The maximum number of treatment 
arms within a trial were 3 (Harland et al., 1991; Morck 
et al., 1993; Booker et al., 2007; Tennant et al., 2014), 
all other trials contained 2 treatment arms. There were a 
total of 8 different metaphylactic antimicrobials (Table 
1). All treatment arms were included in 4 or more trials 
except florfenicol, tildipirosin, and TMS. Florifenicol 
had 3 trials, tildipirosin had 1 trial, and TMS had 1 trial 
included. A placebo control was present in 25 trials.
Forest plots of the mean odds ratio (OR) compari-
sons between antimicrobial and control with 95% CrIs 
for each event outcome are shown in Fig. 2. The dot-
ted line in the center of each forest plot designates the 
OR equal to 1. If the OR are equal to 1, odds of the 
event occurrence are the same for the antimicrobial 
compared to the control; if odds are less than 1, the 
odds for the event occurrence are greater for the con-
trol compared to the antimicrobial; if odds are greater 
than 1, the odds for the event occurrence are greater 
for the antimicrobial compared to the control. BRD 
morbidity cumulative incidence d 1 to ≤ 60 “upper 
tier” treatment arms were tulathromycin, gamithromy-
cin, and tilmicosin. The “middle tier” included ceftio-
fur and oxytetracycline, and the “lesser tier” included 
florfenicol and TMS. Morbidity cumulative incidence 
d 1 to closeout “upper tier” treatment arms included 
tulathromycin, the “middle tier” include tildipirosin, 
gamithromycin, ceftiofur, tilmicosin, and oxytetracy-
cline, and the “lesser tier” included TMS. Mean OR 
for all comparisons between antimicrobials with 95% 
CrIs for each event outcome are shown in Table 2.
For BRD mortality cumulative incidence d 1 to 
closeout and BRD retreatment morbidity d 1 to closeout, 
classifying the treatment arms into tiers was not possible 
due to overlapping 95% CrIs. However, there were some 
differences between individual antimicorbials. In Fig. 
2(c), the 95% CrIs for tulathromycin did not overlap with 
the 95% CrIs of tilmicosin and oxytetracycline. Overall, 
tulathromycin and tilmicosin has a lesser odds than the 
controls, and oxytetracycline is similar to the controls. 
The OR and 95% CrIs of the comparison of tulathromy-
Figure 1. Network of treatment arms for the metaphylactic antimicrobial for BRD morbidity cumulative incidence d 1 to ≤ 60 of the feeding period 
(a), BRD morbidity cumulative incidence d 1 to closeout of the feeding period (b), BRD mortality cumulative incidence d 1 to closeout (c), and BRD 
retreatment morbidity cumulative incidence d 1 to closeout (d) in the mixed treatment comparison meta-analysis. The width of the lines corresponds to the 
number of direct comparisons between antimicrobials, the size of the dot indicates the number of antimicrobials within each arm, and number in parenthesis 
corresponds to the number of comparisons for each antimicrobial.
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cin vs. tilmicosin is 0.26 (0.13 to 0.49) and tulathromycin 
vs. oxytetracycline is 0.20 [0.08 to 0.41; Table 2(c)]. OR 
for tulathromycin is different from tilmicosin and oxy-
tetracycline, and the odds of mortality cumulative inci-
dence d 1 to closeout of the feeding period is 4 times 
greater for tilmicosin than tulathromycin, and 5 times 
greater for oxytetracycline than tulathromycin.
DISCUSSION
The results of the MTC meta-analysis were able to 
accurately identify differences between metaphylactic 
antimicrobials related to BRD morbidity, retreatment, 
and mortality. A wide variety of trials conducted between 
different antimicrobials were identified in the published 
literature. This MTC meta-analysis allows for simultane-
ous inference between treatment arms based on the mod-
el estimates (Lu and Ades, 2004). The data included in 
the MTC meta-analysis performs comparisons between 
the direct and indirect treatments and allows precision 
to increase with the assumption of consistency between 
these antimicrobials (Salanti et al., 2008).
Veterinarians and producers establish a metaphylactic 
treatment protocol based on prior knowledge of the in-
coming group of calves risk factors, season, weight, geo-
graphic origin, prior experience, and published literature 
(Ribble et al., 1995; Snowder et al., 2006; Sanderson et 
al., 2008; USDA, 2011). The overall goal of a metaphy-
lactic antimicrobial is to decrease the risk and negative 
effect of BRD in feedlot cattle. The results from this MTC 
meta-analysis provide veterinarians and producers guid-
ance to more accurately predict the expected outcomes 
when choosing among antimicrobials to use on incoming 
high-risk cattle in a feedlot or stocker operation. For ex-
ample, tulathromycin has the least OR compared to all 
other treatment arms in BRD morbidity cumulative inci-
dence d 1 to ≤ 60 d, BRD morbidity cumulative incidence 
d 1 to closeout, BRD mortality cumulative incidence d 
1 to closeout, and BRD retreatment morbidity cumula-
tive incidence d 1 to closeout outcomes when compared 
to controls (Fig. 2). Tulathromycin is also comparable to 
other antimicrobials for BRD morbidity cumulative inci-
dence d 1 to ≤ 60, because the 95% CrIs of tulathromycin 
overlaps with gamithromycin and tilmicosin (Fig. 2(a)). 
These 3 “upper tier” treatment arms appear comparable in 
the effect differences between controls for the odds of dis-
ease. Results from a MTC meta-analysis can be applied 
to a group of incoming cattle, if this group has a predicted 
BRD morbidity of 30% within the first 60 d of the feeding 
period. If all cattle are administered at arrival an “upper 
tier” treatment with an OR 0.1 to 0.2, then the expected 
BRD morbidity would be about 4% to 8%, or a 80 to 90% 
Figure 2. Forest plots of the odds ratio comparison between individual antimicrobials and control in the mixed treatment comparison with a 95% 
CrIs for BRD morbidity cumulative incidence d 1 to ≤ 60 of the feeding period (a)1, BRD morbidity cumulative incidence d 1 to close out of the feeding 
period (b)2, BRD mortality cumulative incidence d 1 to closeout (c)2, and BRD retreatment morbidity cumulative incidence d 1 to closeout (d)2.   1Binomial 
likelihood, complimentary log-log link, random-effects model. 2Binomial likelihood, logit link, random-effects model.
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reduction in odds of being diagnosed with BRD com-
pared to controls. Overall, this type of analysis has the 
potential to efficiently estimate the odds of disease which 
can be used to assess comparative health, performance, 
and economic outcomes of feedlot and stocker cattle.
Previous meta-analyses have indicated metaphylax-
is can reduce BRD morbidity, and that reduction can be 
from 55% to 29% comparing control cattle to treated (Van 
Donkersgoed, 1992; Wileman et al., 2009). Mortality 
Table 2. The mean odds ratio with 95% credibility inter-
vals for BRD morbidity cumulative incidence d 1 to ≤ 
60 of the feeding period (a)1, BRD morbidity cumulative 
incidence d 1 to close out of the feeding period (b)2, BRD 
mortality cumulative incidence d 1 to closeout (c)2, and 
BRD retreatment cumulative incidence d 1 to closeout 
(d)2 of the mixed treatment comparison meta-analysis. 
The metaphylactic antimicrobial on the left for all odds 











d 1 to  
≤ 60
tilmicosin vs. TMS 3.59 1.19 – 9.30
tilmicosin vs. oxytetracycline 2.16 1.11 – 3.92
tilmicosin vs. florfenicol 3.15 1.26 – 6.68
tilmicosin vs. tulathromycin 0.59 0.27 – 1.14
tilmicosin vs. ceftiofur 1.10 0.43 – 2.43
tilmicosin vs. gamithromycin 0.69 0.39 – 1.15
TMS vs. oxytetracycline 0.74 0.24 – 1.74
TMS vs. florfenicol 1.11 0.26 – 3.03
TMS vs. tulathromycin 0.21 0.05 – 0.57
TMS vs. ceftiofur 0.39 0.09 – 1.14
TMS vs. gamithromycin 0.24 0.07 – 0.58
oxytetracycline vs. florfenicol 1.57 0.54 – 3.56
oxytetracycline vs. tulathromycin 0.30 0.11 – 0.63
oxytetracycline vs. ceftiofur 0.55 0.18 – 1.26
oxytetracycline vs. gamithromycin 0.34 0.16 – 0.62
florfenicol vs. tulathromycin 0.22 0.07 – 0.53
florfenicol vs. ceftiofur 0.41 0.11 – 1.12
florfenicol vs. gamithromycin 0.25 0.09 – 0.55
tulathromycin vs. ceftiofur 2.05 0.65 – 5.07
tulathromycin vs. gamithromycin 1.26 0.64 – 2.27
ceftiofur vs. gamithromycin 0.73 0.29 – 1.55
(b) BRD 
morbid-
ity d 1 to 
closeout
tilmicosin vs. TMS 2.07 1.11 – 3.56
tilmicosin vs. oxytetracycline 1.29 0.94 – 1.77
tilmicosin vs. tulathromycin 0.23 0.16 – 0.32
tilmicosin vs. ceftiofur 0.97 0.54 – 1.62
tilmicosin vs. gamithromycin 0.64 0.35 – 1.08
tilmicosin vs. tildipirosin 0.50 0.27 – 0.83
TMS vs. oxytetracycline 0.67 0.37 – 1.14
TMS vs. tulathromycin 0.12 0.06 – 0.22
TMS vs. ceftiofur 0.51 0.21 – 1.04
TMS vs. gamithromycin 0.34 0.14 – 0.69
TMS vs. tildipirosin 0.26 0.11 – 0.53
oxytetracycline vs. tulathromycin 0.18 0.12 – 0.27
oxytetracycline vs. ceftiofur 0.77 0.39 – 1.36
oxytetracycline vs. gamithromycin 0.51 0.25 – 0.92
oxytetracycline vs. tildipirosin 0.39 0.20 – 0.70
tulathromycin vs. ceftiofur 4.43 2.17 – 7.88
tulathromycin vs. gamithromycin 2.94 1.41 – 5.28
tulathromycin vs. tildipirosin 2.27 1.10 – 4.06
ceftiofur vs. gamithromycin 0.71 0.30 – 1.43
ceftiofur vs. tildipirosin 0.55 0.23 – 1.12











ity d 1 to 
closeout
tilmicosin vs. TMS 1.35 0.28 – 3.84
tilmicosin vs. oxytetracycline 1.44 0.74 – 2.70
tilmicosin vs. tulathromycin 0.26 0.13 – 0.49
tilmicosin vs. ceftiofur 0.88 0.25 – 2.02
tilmicosin vs. gamithromycin 1.96 0.44 – 5.43
tilmicosin vs. tildipirosin 1.21 0.32 – 3.17
TMS vs. oxytetracycline 1.64 0.37 – 4.82
TMS vs. tulathromycin 0.31 0.06 – 1.00
TMS vs. ceftiofur 1.07 0.14 – 3.56
TMS vs. gamithromycin 2.86 0.25 – 8.95
TMS vs. tildipirosin 1.52 0.17 – 5.41
oxytetracycline vs. tulathromycin 0.20 0.08 – 0.41
oxytetracycline vs. ceftiofur 0.74 0.15 – 1.75
oxytetracycline vs. gamithromycin 1.52 0.27 – 4.60
oxytetracycline vs. tildipirosin 1.02 0.19 – 2.70
tulathromycin vs. ceftiofur 3.81 0.83 – 9.42
tulathromycin vs. gamithromycin 8.41 1.45 – 25.26
tulathromycin vs. tildipirosin 5.39 1.03 – 14.73
ceftiofur vs. gamithromycin 3.38 0.42 – 10.70
ceftiofur vs. tildipirosin 2.01 0.30 – 6.41





ity d 1 to 
closeout
tilmicosin vs. oxytetracycline 1.00 0.59 – 1.60
tilmicosin vs. tulathromycin 0.50 0.22 – 0.98
tilmicosin vs. ceftiofur 0.82 0.39 – 1.52
tilmicosin vs. gamithromycin 0.86 0.37 – 1.70
tilmicosin vs. tildipirosin 1.38 0.60 – 2.69
oxytetracycline vs. tulathromycin 0.52 0.22 – 1.01
oxytetracycline vs. ceftiofur 0.90 0.34 – 1.85
oxytetracycline vs. gamithromycin 0.93 0.33 – 2.05
oxytetracycline vs. tildipirosin 1.67 0.54 – 3.24
tulathromycin vs. ceftiofur 2.04 0.62 – 4.65
tulathromycin vs. gamithromycin 2.06 0.59 – 5.13
tulathromycin vs. tildipirosin 3.39 0.97 – 8.09
ceftiofur vs. gamithromycin 1.30 0.37 – 2.88
ceftiofur vs. tildipirosin 1.94 0.61 – 4.53
gamithromycin vs. tildipirosin 2.01 0.55 – 4.77
1Binomial likelihood, complimentary log-log link, random-effects model.
2Binomial likelihood, logit link, random-effects model.
3The antimicrobial on the left of each comparison is the denominator in 
the ratio, and the antimicrobial on the right is the numerator. If the OR are 
equal to 1, odds of the event occurrence are the same for each antimicro-
bial; if odds are less than 1, the odds for the event occurrence are greater 
for the antimicrobial on the left; if odds are greater than 1, the odds for the 
event occurrence are greater for the antimicrobial on the right.
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due to BRD has also been reported to be reduced from 
3.8% to 1.8% for cattle not receiving metaphylaxis com-
pared to those that do receive metaphylaxis (Wileman 
et al., 2009). The results from this MTC meta-analysis 
presented similar results; cattle treated with an antimi-
crobial have a reduced OR compared to controls for mor-
bidity (Fig. 2) and allows producers and veterinarians to 
compare efficacy between antimicrobials, to determine 
antimicrobials that are similar (i.e., no difference), and 
antimicrobials that may be superior to other antimicrobi-
als (i.e., a difference exists).
Event outcome for BRD mortality in Fig. 2(c) had 
overlapping 95% CrIs for all the treatment arms making 
full interpretation of these antimicrobial comparisons 
challenging. The lack of identified differences between 
multiple treatments arms may be due to the low inci-
dence of mortality in feedlots (Snowder et al., 2006), 
and the incidence was low in the studies included in the 
analysis which most likely contributes to the overlap-
ping CrIs. The lack of differences does not imply ob-
served differences would not be higher in populations 
at a higher risk for BRD mortality.
In the US, 59% of all feedlot cattle are treated with 
a metaphylactic antimicrobial at arrival (USDA, 2011). 
Analyzing retreatment of cattle diagnosed with BRD 
after metaphylactic administration is beneficial in de-
termining the overall affect the metaphylactic antimi-
crobial has on BRD morbidity, treatment success, and 
mortality. Retreatment for the present study refers to an-
imals initially diagnosed with BRD and treated with an 
antimicrobial that required an additional antimicrobial 
for BRD. The results from this MTC meta-analysis for 
the BRD retreatment morbidity cumulative incidence 
were challenging to interpret, event outcome for BRD 
retreatment morbidity in Fig. 2(d) had overlapping 95% 
CrIs for all the antimicrobial arms. An analysis to com-
pare retreatment protocols after initial metaphylactic 
administration was attempted, but was unsuccessful 
due to few trials with similar BRD retreatment morbid-
ity protocols that could be compared.
The prevalence of BRD morbidity differs among 
days following feedlot arrival (Babcock et al., 2010). 
The reported trial days in the treatment period d 1 to 
≤ 60 were variable in the total days at risk for calves. 
Accounting for variability days at risk for treatment 
periods is necessary when analyzing the odds of dis-
ease for a MTC meta-analysis which we accomplished 
using the binomial likelihood, complimentary log-log 
link, random-effects model for combining direct and 
indirect evidence in mixed treatment comparisons us-
ing a Bayesian approach. While this model accounts 
for days at risk, it cannot account for a skewed distri-
bution of morbidity case occurrence in the first 60 d.
When a study is published, reporting all aspects 
of the design, such as blinding, randomization, and al-
location to treatment units, is crucial to perform a MTC 
meta-analysis. Because of incomplete reporting, making 
decisions based on published literature can be hampered 
due to limited data and subjective prediction (Pollreisz 
et al., 1991; Jackson, 2006). Previous publications have 
reported lack of reporting of crucial aspects of trials and 
the influence the inclusion or exclusion of specific trials 
have on the final analysis of a systematic review or meta-
analysis (Van Donkersgoed, 1992; O’Connor et al., 2013; 
Theurer et al., 2015). A limitation of this project included 
the limited published literature for many of the metaphy-
lactic treatments. Inconsistency may increase when later 
publications are combined with earlier publications due 
to changes in cattle, pathogens, or management over time, 
and careful consideration should be made when interpret-
ing results from a MTC meta-analysis if the data between 
trials appears to be inconsistent (Mills et al., 2012).
Conclusion
The results from this MTC meta-analysis identi-
fied differences between parenteral metaphylactic an-
timicrobial options currently available. Metaphylactic 
antimicrobial options appear to offer different effects 
on BRD morbidity and mortality odds in feedlot and 
stocker cattle. Further research is needed to determine 
the effects of different metaphylactic antimicrobials 
on the BRD mortality, retreatment morbidity, perfor-
mance, and economics of feedlot cattle.
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